25 related articles for article (PubMed ID: 36599822)
1. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
McCarter JGW; Nemirovsky D; Famulare CA; Farnoud N; Mohanty AS; Stone-Molloy ZS; Chervin J; Ball BJ; Epstein-Peterson ZD; Arcila ME; Stonestrom AJ; Dunbar A; Cai SF; Glass JL; Geyer MB; Rampal RK; Berman E; Abdel-Wahab OI; Stein EM; Tallman MS; Levine RL; Goldberg AD; Papaemmanuil E; Zhang Y; Roshal M; Derkach A; Xiao W
Blood Adv; 2023 Sep; 7(17):5000-5013. PubMed ID: 37142255
[TBL] [Abstract][Full Text] [Related]
2. Presence but not number of secondary type mutations influences outcome in de novo AML without MDS-associated or recurring cytogenetic abnormalities.
Weinberg OK; Cantu MD; Gagan J; Madanat YF; Arber DA; Hasserjian RP
EJHaem; 2023 Aug; 4(3):760-764. PubMed ID: 37601841
[TBL] [Abstract][Full Text] [Related]
3. Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia.
Song GY; Kim HJ; Kim T; Ahn SY; Jung SH; Kim M; Yang DH; Lee JJ; Kim MY; Cheong JW; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Park SK; Kim SH; Choi CK; Kim HJ; Ahn JS; Kim DDH
Sci Rep; 2024 Apr; 14(1):8517. PubMed ID: 38609396
[TBL] [Abstract][Full Text] [Related]
4. A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria.
Zhou Q; Zhao D; Zarif M; Davidson MB; Minden MD; Tierens A; Yeung YWT; Wei C; Chang H
Blood Adv; 2024 Apr; 8(7):1760-1771. PubMed ID: 38286462
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification.
Hochman MJ; Othus M; Hasserjian RP; Ambinder A; Brunner A; Percival MM; Hourigan CS; Swords R; DeZern AE; Estey EH; Karp JE
Leukemia; 2023 Sep; 37(9):1915-1918. PubMed ID: 37524919
[TBL] [Abstract][Full Text] [Related]
6. Genetic, Phenotypic, and Clinical Heterogeneity of NPM1-Mutant Acute Myeloid Leukemias.
Testa U; Pelosi E; Castelli G
Biomedicines; 2023 Jun; 11(7):. PubMed ID: 37509445
[TBL] [Abstract][Full Text] [Related]
7. Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting.
Attardi E; Savi A; Borsellino B; Piciocchi A; Cipriani M; Ottone T; Fabiani E; Divona M; Travaglini S; Pascale MR; Awada H; Durmaz A; Visconte V; Della Porta MG; Venditti A; Maciejewski JP; Gurnari C; Voso MT
Blood Adv; 2023 Sep; 7(17):5122-5131. PubMed ID: 37327116
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia.
Daneshbod Y; Kohan L; Taghadosi V; Weinberg OK; Arber DA
Curr Treat Options Oncol; 2019 Feb; 20(2):15. PubMed ID: 30741367
[TBL] [Abstract][Full Text] [Related]
9. Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy.
Yang G; Wang X; Huang S; Huang R; Wei J; Wang X; Zhang X
Front Immunol; 2022; 13():1034438. PubMed ID: 36268012
[TBL] [Abstract][Full Text] [Related]
10. Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML.
Tsai XC; Sun KJ; Lo MY; Tien FM; Kuo YY; Tseng MH; Peng YL; Chuang YK; Ko BS; Tang JL; Sun HI; Liu MC; Liu CW; Lin CC; Yao M; Chou WC; Hou HA; Tien HF
Blood Cancer J; 2023 Jan; 13(1):4. PubMed ID: 36599822
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
[TBL] [Abstract][Full Text] [Related]
13. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
14. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
15. Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations.
Chou SC; Tang JL; Hou HA; Chou WC; Hu FC; Chen CY; Yao M; Ko BS; Huang SY; Tsay W; Chen YC; Tien HF
Leuk Res; 2014 Nov; 38(11):1278-84. PubMed ID: 25260824
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
